Skip to content

The Criteria for Lymph Node Sorting for Pathological Examination in Gastric Cancer

A Single Center Randomized Prospective Study on the Criteria for Lymph Node Sorting for Pathological Examination After Curative Surgery for Gastric Cancer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03478449
Enrollment
276
Registered
2018-03-27
Start date
2018-04-01
Completion date
2020-12-30
Last updated
2020-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exanimation, Gastric Cancer, Lymph Node Metastases

Brief summary

The aim of this study is intending to provide the optimal procedures of lymph node sorting for pathological examination after curative surgery for gastric cancer, which can discriminate the differences of the status of lymph node metastasis, pTNM classification and prognostic outcome of gastric cancer patients.

Interventions

PROCEDURElymph node sorting for pathological examination

In this study, intervention methods include two kinds of lymph node sorting for pathological examination in gastric cancer samples after curative surgery. One is the fine sorting lymph nodes, representing the lymph nodes should be sorted one by one from the tissues around the stomach, celiac axis, and the main brunches of celiac axis. The other is the group sorting lymph nodes, representing the lymph nodes should be simply sorted in the soft tissues around the stomach, celiac axis, and the main brunches of celiac axis.

Sponsors

Tianjin Medical University Cancer Institute and Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* 1\) Physical conditions compliance with the requirements for curative gastrectomy * 2\) Consent to undergo the D2 lymphadenectomy * 3\) Comply with the protocol during the whole study period * 4\) No neoadjuvant therapy administration * 5\) Sign informed consent and permission of withdraw in the whole study period * 6\) Consent to provide the tissue specimens after surgery for this study * 7\) Pathological examination confirmation the adenocarcinoma of stomach before surgery * 8\) Estimation the overall survival after surgery no less than 6 months * 9\) No anesthesia or operation contraindication disease * 10\) cTanyNanyM0 stage demonstration by CT and endoscopic ultrasonography examinations * 11\) Negative cytological detection in operation * 12\) No seriously concomitance's diseases * 13\) Karnofsky Performance Scores (KPS) more than 60

Exclusion criteria

* 1\) Women during pregnant stage and breast-feed stage * 2\) Women of childbearing age without any contraceptive measures * 3\) Severe congestive heart failure, frequent arrhythmia, or myocardial infarction within 12 months * 4\) Immunosuppressive therapists for organ transplantation * 5\) Seriously uncontrolled recurrent infection * 6\) other malignant tumors * 7\) No abilities of self-knowledge or mental disorders * 8\) Participating in other clinical trials * 9\) Siewert I and II esophagogastric junction tumors * 10\) Serious internal diseases obstruction surgery

Design outcomes

Primary

MeasureTime frameDescription
Migration of pN stage in gastric cancer patients60 monthsAccording to the overall survival of all included patients, we will evaluate the optimal lymph node sorting method to obtain the accurately pathological stage of lymph node metastatic counts (pN stage) for prediction the prognosis of patients after curative surgery for gastric cancer.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026